SUBSCRIBE
SUBSCRIBE

Biogen

NEWS
Investors Sigh With Relief as Biogen's Alzheimer's Drug Delivers in Early-Stage Study
Deals
Is Biogen Even Buyout Worthy?
September 6, 2016
 · 
3 min read
Deal Spree Continues as Allergan Inks $2.47 Billion Deal for This Bay Area Biotech
Deals
Allergan’s Brent Saunders Denies Interest in Biogen or Big M&A
August 10, 2016
 · 
3 min read
Investors Sigh With Relief as Biogen's Alzheimer's Drug Delivers in Early-Stage Study
Business
Biogen Unveils Name for New Standalone Hemophilia-Focused Company: Bioverativ
August 9, 2016
 · 
3 min read
Investors Sigh With Relief as Biogen's Alzheimer's Drug Delivers in Early-Stage Study
Deals
Biogen Not Pursuing an Acquisition, Says Source
August 4, 2016
 · 
3 min read
Investors Sigh With Relief as Biogen's Alzheimer's Drug Delivers in Early-Stage Study
Deals
Despite Skepticism, Biogen Stock Explodes After Merck & Co. and Allergan Takeover Speculation
August 2, 2016
 · 
3 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Biotech Bay
A Look at Four Biotech Giants’ Q2 Earnings
July 29, 2016
 · 
3 min read
How Biogen Makes Most of Its Cash
Deals
Speculation Heats Up on Biogen as an Acquisition Target or Starting a Buying Spree
July 25, 2016
 · 
3 min read
How Biogen Makes Most of Its Cash
Business
As Biogen Boss Moves to the Bay Area, California Biotechs Pay Attention
July 22, 2016
 · 
2 min read
How Biogen Makes Most of Its Cash
Business
Biogen CEO Steps Down Amid Stellar Q2 Financials, Hunt for New Leader Begins
July 21, 2016
 · 
3 min read
Load More
AWARDS
  • 2022 Best Places to Work
  • 2023 Best Places to Work
JOBS
IN THE PRESS
Press Releases
The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS
December 23, 2025
 · 
13 min read
Press Releases
Canadian HTA Assessments Recognize Therapeutic Value of QALSODY™ (tofersen injection) and its Potential to Modify Disease Progression in Individuals Living with SOD1-ALS
December 11, 2025
 · 
6 min read
Press Releases
Biogen Receives Health Canada Authorization for ZURZUVAE™ (zuranolone), the First and Only Treatment Indicated for Adults with Postpartum Depression in Canada
December 10, 2025
 · 
8 min read
Press Releases
“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Included in China’s Commercial Insurance Innovative Drug List
December 9, 2025
 · 
11 min read
Press Releases
Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
December 8, 2025
 · 
19 min read
Press Releases
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
December 8, 2025
 · 
19 min read
Press Releases
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025
December 4, 2025
 · 
24 min read
Press Releases
New Data Presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
December 3, 2025
 · 
21 min read
Press Releases
Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
December 2, 2025
 · 
16 min read
Press Releases
Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
December 2, 2025
 · 
16 min read
Load More